Core Insights - PetVivo Holdings, Inc. has successfully upgraded to trade on the OTCQX Best Market, enhancing its visibility and accessibility for investors [1][3][6] - The company specializes in innovative biomedical devices and therapeutics for horses and companion animals, with key products including SPRYNG with OsteoCushion Technology and PrecisePRP [1][4][5] Company Overview - PetVivo Holdings, Inc. focuses on the manufacturing, commercialization, and licensing of medical devices and therapeutics for equine and companion animals, leveraging human therapies for efficient treatment [7][8] - The company has a robust pipeline of products protected by twelve patents and six trade secrets, indicating a strong intellectual property position [8] Product Details - SPRYNG with OsteoCushion Technology is an injectable veterinary medical device that aids in managing joint pain by restoring proper joint mechanics [4] - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product designed for veterinarians, providing a consistent dose of 4 billion platelets per vial [5]

Company Overview - PetVivo Holdings Inc. is an emerging biomedical device company based in Edina, Minnesota, focused on licensing and commercialization of innovative medical devices and therapeutics for equine and companion animals [5][6] - The company aims to leverage investments in human bio-materials and medical device industries to efficiently commercialize products for animals [5] - PetVivo has a robust pipeline of products, including twelve patents and six trade secrets protecting its biomaterials and methods [6] Market Position - PetVivo Holdings has upgraded to trade on the OTCQX Best Market from the OTCQB Venture Market, marking a significant milestone for the company [1][3] - Trading on OTCQX enhances the company's visibility within the investment community and provides greater liquidity and accessibility for investors [4] Product Offerings - The company's lead products include SPRYNG with OsteoCushion technology, an intra-articular injection for managing lameness and joint-related afflictions in animals, and PrecisePRP, a first-in-class platelet-rich plasma product for veterinary use [6]